



An Artificially Intelligent  
Diagnostic Assistant  
for gastric inflammation



## Introducing AIDA

AIDA is one of 13 European projects to obtain funding through the Horizon Europe program in the HORIZON-HLTH-2022-STAYHLTH-02-01 call for proposals, having been selected from among the 72 proposals submitted within the health cluster. AIDA is a four-year project, financed by over 7 million euros between European and British funding, and coordinated by Dr. Tania Fleitas (INCLIVA, Spain). The AIDA consortium includes leading European authorities in the field of gastric inflammation, gastric cancer, AI and machine learning experts, experts on data governance and privacy, and representatives from industry, public administration, and patient advocacy.

Most cases of gastric cancer (GC) are detected at a late stage, when patients have a median life expectancy of about a year. Diagnosing people at risk of developing GC at the pre-symptomatic stage, typically with chronic gastric inflammation, could significantly improve the outlook.

AIDA's main goals include understanding the mechanisms that trigger gastric oncogenesis, diagnosis of precancerous inflammation at the earliest possible stage, suggesting personalised therapeutic strategies for treatment and follow-up leading to more effective treatment plans, along with patient health monitoring and personalised recommendations, thus efficiently contributing to gastric cancer prevention.



Co-funded by  
the European Union



UK Research  
and Innovation

Funded by the European Union under the Horizon Europe Framework Programme, Grant Agreement N°: 101095359. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Commission. Neither the European Union nor the European Health and Digital Executive Agency can be held responsible for them.

Supported by the UK Research and Innovation (Grant Agreement N°: 10058099)



An Artificially Intelligent  
Diagnostic Assistant  
for gastric inflammation



## Clinical expected outcomes

*improved prediction of gastric inflammation and prevention of gastric cancer*

Artificial intelligence (AI) can help clinicians make sense of their own data by automating much of the treatment and analysis, which require manual work and years of experience. But it can do more: it can bring together available data from various sources into a vast data lake and cross-correlate the data to derive a 'risk score' for GC and shed light on the mechanisms of its evolution. AI will help to: identify precancerous lesions (dysplasia or subtypes of intestinal metaplasia) using images, enhance risk assessment, provide additional decision support, and implement models in clinical practice.

## AI and data innovativeness

*how data and AI models can help clinicians*

AIDA will be certified as a medical device with (mobile) apps, dashboards and sensors to help clinicians monitor their patients' health status at every stage of the pathway. Aida's ambition is to analyse data from global partners for prevention and a reliable, early diagnosis of chronic gastric inflammation. This will help clinicians and patients deliver personalised prevention measures and reduce the burden of chronic gastric inflammation and gastric cancer.

## Consortium details

The consortium involves **12 centres of excellence** from **8 European countries**, with a **multidisciplinary team** including some of the leading European authorities on gastric inflammation and cancer, experts in bioinformatics, artificial intelligence and machine learning and in data governance and privacy, representatives of the public administration and patient advocates.



## Contact details

[aida.project@incliva.es](mailto:aida.project@incliva.es)

Page 2 of 2